Harald Holte

Senior consultant, head of lymphoma section

University of Oslo

Norway

Research Interests

Explore related searches

Professors in Norway

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (8)

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (9)

Judit Meszaros Joergensen

Aarhus University

DENMARK

View details

Suvi-Katri Leivonen

University of Helsinki

FINLAND

View details

Joshua Philipp Entrop

Karolinska Institutet

SWEDEN

View details

Edmund K. Waller

Professor

Winship Cancer Institute of Emory University

UNITED STATES

View details

Sirpa Leppä

University of Helsinki

FINLAND

View details

Thomas Stauffer Larsen

Odense University Hospital

DENMARK

View details

Eva Kimby

Karolinska University Hospital

SWEDEN

View details

Heli Vajavaara

University of Helsinki

FINLAND

View details

Daniel Molin

Associate Professor

Uppsala University

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Harald Holte

Research Interests

Explore related searches

Contact this professor

Articles (8)

Reproduction patterns among non‐Hodgkin lymphoma survivors by subtype in Sweden, Denmark and Norway: A population‐based matched cohort study

Reproduction patterns among classical Hodgkin lymphoma survivors treated with BEACOPP and ABVD in Sweden, Denmark and Norway—A population‐based matched cohort study

Low lymphocyte‐to‐monocyte ratio predicts poor outcome in high‐risk aggressive large B‐cell lymphoma

Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress

The simplified follicular lymphoma PRIMA‐prognostic index is useful in patients with first‐line chemo‐free rituximab‐based therapy

Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma

Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real‐world patients

No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

Collaborators (9)

Judit Meszaros Joergensen

Suvi-Katri Leivonen

Joshua Philipp Entrop

Edmund K. Waller

Sirpa Leppä

Thomas Stauffer Larsen

Eva Kimby

Heli Vajavaara

Daniel Molin

Make your next move.